Acaluxen 100mg, Acalabrutinib Capsules
Acalabrutinib (brand name Calquence) Acaluxen 100mg is a targeted therapy used in the treatment of specific types of blood cancers. It is a Bruton’s tyrosine kinase (BTK) inhibitor, meaning it works by blocking a protein that helps cancer cells grow and multiply.
What Is Acaluxen 100mg (Acalabrutinib)?
Acalabrutinib, a selective inhibitor of Bruton’s tyrosine kinase (BTK), is available under the brand name Acaluxen 100mg. The survival and proliferation of malignant B cells depend on B-cell receptor signaling, which Acaluxen 100mg disrupts this signaling pathway, leading to the death of cancerous B cells. This medication is primarily used in the treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL)
How to Work
Acalabrutinib works by irreversibly binding to BTK, thereby inhibiting its activity. This inhibition prevents B-cell receptor signaling, which is essential for the survival and proliferation of malignant B cells. As a result, Acaluxen 100mg effectively reduces the number of cancerous B cells in the body .
How to Use
Acaluxen 100mg is administered orally. The standard dosing regimen is 100 mg taken twice daily, approximately 12 hours apart.
How to Take
- Dosage: 100 mg twice daily.
- Timing: Take at the same time each day to help remember.
- Handling: Because the medication can be absorbed through the skin and could harm an unborn child, do not handle the pills if you are pregnant or want to become pregnant.
Other Dosage Forms
Acaluxen 100mg is available in tablet form. Each tablet contains 100 mg of acalabrutinib. There are no other dosage forms currently available for this medication
Side Effects
Common side effects of Acaluxen 100mg include:
- Headache
- Diarrhea
- Muscle and joint pain
- Upper respiratory tract infections
- Bruising
Serious side effects may include:
- Serious infections, which can be fatal
- Second primary cancers, including skin cancers
- Heart rhythm problems (e.g., atrial fibrillation)
- Liver problems
Prescription
Acaluxen 100mg is a prescription medication. Only a medical professional with competence in administering anticancer treatments should supervise its administration. Tell your doctor about all of your health issues and any additional medications you are taking before beginning therapy.
Interaction
- Acaluxen 100mg can interact with other medications, which may affect its efficacy or increase the risk of side effects.
- Acalabrutinib concentrations may rise due to moderate CYP3A inhibitors; dosage adjustments may be required.
- Gastric acid-reducing medications have the potential to decrease acalabrutinib plasma concentrations. When using antacids or H2-receptor antagonists, space out your dosage by at least two hours. Proton pump inhibitors should be avoided.
FAQs
Q: What is Acaluxen used for?
A: Acalabrutinib is used to treat adults with mantle cell lymphoma (MCL) who have received at least one prior therapy, and adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Q: How long will I need to take Acaluxen ?
A: Treatment with Acalabrutinib is typically continued until disease progression or unacceptable toxicity. This can mean long-term treatment for chronic conditions like CLL.
Q: What should I avoid while taking Acaluxen ?
A: Avoid grapefruit and grapefruit juice. Discuss all other medications and supplements with your doctor, especially strong CYP3A inhibitors/inducers and blood thinners.
Conclusion
Acalabrutinib (Acaluxen 100mg) is a significant advancement in the treatment of certain B-cell malignancies, offering a targeted approach to inhibit BTK and control disease progression. Its selectivity helps provide a more tolerable treatment option for many patients. However, like all potent medications, it comes with potential side effects and interactions that necessitate careful monitoring and patient education. Adherence to prescribed dosage, timely reporting of adverse events, and open communication with healthcare providers are crucial for safe and effective treatment with Acalabrutinib.
